Earnings Call Excerpt
InSite Vision Inc. (ISV)
Wall Street Analyst Forum
September 10, 2008 2:00 pm ET
Executives
S. Kumar Chandrasekaran - Chairman, President and CEO
Presentation
Moderator
Good afternoon, ladies and gentlemen. I like to introduce the next company in this afternoon’s biotechnology and specialty pharmaceutical program. I have mentioned earlier in the day that all the forty minute presentations and Q&A sessions are webcast and they are live but they are also retrievable, so if there is a meeting you would like to re-attend or our PowerPoint presentation you like to re-access, they are all retrievable for full 30 days from the live event. They are all easily accessible through the individual company website. 99% of the companies have link directly to the webcast and Merck will leave those links up for at least a month.
The next company in this afternoon’s program is InSite Vision. They develop novel ocular pharmaceutical products using their DuraSite bioadhesive polymer core technology to enable topical delivery and sustained release of existing drug molecules for reduced frequency of treatment and improved efficacy. This approach is designed to enable the company developed products at a lower cost or at lower risk in cost and a new chemical entity and is intended to provide patients with product alternatives that will encourage compliance for better treatment outcomes.
Our formulated and well established antibiotic azithromycin in DuraSite, InSite developed the lowest-dosing ocular antibiotic available to the U.S. ophthalmic market. AzaSite, 1% was launched in the United States in August 2007 by Inspire Pharmaceuticals for the topical treatment of bacterial conjunctivitis, pink eye. InSite is also building a network of international partners for the commercialization and distribution of AzaSite outside the United States. InSite continues to expand its portfolio of ophthalmic antibiotic products based on the DuraSite product platform.
For further introduction, let me introduce the company. We have with us both the Chairman and the Chief Executive Officer of the company as well their Senior Director of Investor Relations.
S. Kumar Chandrasekaran
Good afternoon. It is always a challenge to be the last speaker in a symposium especially on a wonderful New York afternoon and I say it is wonderful New York because these are the days we would normally have in California all the time. With your kind information what I would like to do is to try and make this presentation as interactive as possible. We do not have to go into another separate breakout room and so you can just interrupt me if you have any questions during the presentation and I will try and make it as user friendly as I possibly can.
- To read the full transcript on Seeking Alpha, click here »
